Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Isofol Medical

0.879

 

SEK

 

-2.93 %

Less than 1K followers

ISOFOL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Compare
-2.93%
-8.65%
-43.45%
-57.61%
-54.94%
-51.09%
-86.72%
-85.35%
-93.48%

Isofol Medical is a research-based biotechnology company working to improve the prognosis of patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment that is used globally for several forms of solid tumors. Isofol is conducting clinical development of arfolitixorin in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is great.

Read more
Market cap
247.09M SEK
Turnover
868.43K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
26.8.
2025

Interim report Q2'25

12.11.
2025

Interim report Q3'25

18.2.
2026

Annual report '25

All
Webcasts
Press releases
3rd party
ShowingAll content types
Regulatory press release7/4/2025, 4:00 PM

Isofol's rights issue fully subscribed – exercises overallotment for Japanese partner

Isofol Medical
Press release6/17/2025, 7:35 AM

Redeye: Redeye Initiates Coverage of Isofol Medical

Isofol Medical
Regulatory press release6/17/2025, 6:40 AM

Isofol publishes prospectus in connection with the company’s rights issue

Isofol Medical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Press release6/12/2025, 6:00 AM

Isofol completes first cohort in ongoing clinical study with arfolitixorin

Isofol Medical
Regulatory press release6/11/2025, 12:00 PM

Bulletin from extraordinary general meeting in Isofol Medical AB (publ) held on 11 June 2025

Isofol Medical
Regulatory press release6/5/2025, 6:30 AM

Isofol announces final terms of the rights issue and the potential overallotment issue

Isofol Medical
Press release6/3/2025, 6:00 AM

Isofol announces the launch of new Advisory Board in connection with ASCO 2025

Isofol Medical
Press release6/2/2025, 6:00 AM

Isofol granted Pre-IND meeting with the FDA for arfolitixorin

Isofol Medical
Regulatory press release5/21/2025, 2:40 PM

Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 21, 2025

Isofol Medical
Regulatory press release5/21/2025, 6:00 AM

Isofol Medical AB (publ) publishes Interim report, January – March 2025

Isofol Medical
Press release5/14/2025, 6:15 AM

Interview with Isofol’s CEO Petter Segelman Lindqvist on upcoming rights issue

Isofol Medical
Regulatory press release5/12/2025, 6:45 AM

Notice to attend the Extraordinary General Meeting held on June 11, 2025 in Isofol Medical AB (publ)

Isofol Medical
Regulatory press release5/12/2025, 6:30 AM

The Board of Directors of Isofol resolves on a fully guaranteed Rights Issue of units amounting to approximately SEK 85 million and proposes an over-allotment issue of approximately SEK 10 million

Isofol Medical
Press release4/28/2025, 6:15 AM

Isofol includes first patient in a clinical phase Ib/II study of arfolitixorin

Isofol Medical
Regulatory press release4/17/2025, 6:00 AM

Notice to attend the Annual General Meeting held on May 21, 2025 in Isofol Medical AB (publ)

Isofol Medical
Regulatory press release4/11/2025, 6:00 AM

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2024

Isofol Medical
Press release4/3/2025, 6:00 AM

Isofol’s partner Solasia intends to increase investments in upcoming trials with arfolitixorin

Isofol Medical
Press release3/27/2025, 8:30 AM

Isofol establish advisory board with leading experts

Isofol Medical
Regulatory press release3/21/2025, 11:05 AM

Isofol receives regulatory approval to initiate clinical study of arfolitixorin

Isofol Medical
Press release3/17/2025, 10:30 AM

Isofol expands network of advisors with prominent expert

Isofol Medical
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.